Modality
Radioligand
MOA
PD-L1i
Target
CD19
Pathway
Proteasome
Cervical Ca
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
~Nov 2020
→ ~Feb 2022
Phase 3
May 2022
→ Oct 2030
Phase 3Current
NCT04967425
101 pts·Cervical Ca
2022-05→2025-05·Recruiting
NCT05166749
1,229 pts·Cervical Ca
2023-10→2030-10·Not yet recruiting
NCT08632460
1,610 pts·Cervical Ca
2023-09→2028-06·Recruiting
2,940 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-2510mo agoPh3 Readout· Cervical Ca
2028-06-262.2y awayPh3 Readout· Cervical Ca
2030-10-214.6y awayPh3 Readout· Cervical Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Recruit…
P3
Recruit…
P3
Not yet…
Catalysts
Ph3 Readout
2025-05-25 · 10mo ago
Cervical Ca
Ph3 Readout
2028-06-26 · 2.2y away
Cervical Ca
Ph3 Readout
2030-10-21 · 4.6y away
Cervical Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04967425 | Phase 3 | Cervical Ca | Recruiting | 101 | eGFR |
| NCT05166749 | Phase 3 | Cervical Ca | Not yet recr... | 1229 | CR |
| NCT08632460 | Phase 3 | Cervical Ca | Recruiting | 1610 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |